| 3.56 0.1 (2.89%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.78 | 1-year : | 5.59 |
| Resists | First : | 4.09 | Second : | 4.78 |
| Pivot price | 3.05 |
|||
| Supports | First : | 3.28 | Second : | 2.77 |
| MAs | MA(5) : | 3.49 |
MA(20) : | 3 |
| MA(100) : | 3.24  |
MA(250) : | 4.91 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.2 |
D(3) : | 51.8 |
| RSI | RSI(14): 67.3 |
|||
| 52-week | High : | 7.86 | Low : | 2.73 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MEIP ] has closed below upper band by 10.0%. Bollinger Bands are 126.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.6 - 3.62 | 3.62 - 3.63 |
| Low: | 3.38 - 3.39 | 3.39 - 3.4 |
| Close: | 3.53 - 3.56 | 3.56 - 3.58 |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Fri, 26 Jul 2024
MEI Pharma (NASDAQ:MEIP) Receives New Coverage from Analysts at StockNews.com - Defense World
Wed, 24 Jul 2024
MEI Pharma (NASDAQ:MEIP) Downgraded by Brookline Capital Management - Defense World
Tue, 23 Jul 2024
MEI Pharma (NASDAQ:MEIP) Downgraded by Laidlaw - Defense World
Mon, 22 Jul 2024
MEI Pharma initiates strategic review and layoffs By Investing.com - Investing.com South Africa
Mon, 22 Jul 2024
MEIP - MEI Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Mon, 22 Jul 2024
MEI Pharma plans workforce reduction as part of strategic alternatives (NASDAQ:MEIP) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 43.3 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | 3.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.65 |
| Profit Margin | 39.1 % |
| Operating Margin | 30.5 % |
| Return on Assets (ttm) | 12.3 % |
| Return on Equity (ttm) | 61.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 10.02 |
| EBITDA (p.s.) | 3.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | 0.9 |
| PEG Ratio | -7.9 |
| Price to Book value | 0.46 |
| Price to Sales | 0.35 |
| Price to Cash Flow | -0.55 |
| Dividend | 1.75 |
| Forward Dividend | 0 |
| Dividend Yield | 49.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|